Skip to main content

Foresite Capital — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

129
Companies
$15.2B
Total invested
$143.0M
Avg. check
18
Industries
Biotechnology 22Health Care 19Therapeutics 13Life Science 8Medical 8Pharmaceutical 7+12 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 129
Wave Life Sciences
December 2025

Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases

Biotechnology · Boston$350.0M Post-IPO Equity
TenSixteen Bio
January 2022

TenSixteen Bio is a biotechnology company focused on developing novel therapeutics for a variety of diseases.

Biotechnology · San Francisco$40.0M Series A
Pardes Biosciences
December 2021

Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.

Biotechnology · Carlsbad$75.0M Post-IPO Equity
Aeovian Pharmaceuticals
December 2025

Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.

Biopharma · San Francisco$55.0M Series B
Tasso
December 2021

Tasso is a Medical innovation company changing the way diagnostics are delivered

Health Care · Seattle$100.0M Series B
Mythic Therapeutics
December 2021

Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics.

Biotechnology · Waltham$103.0M Series B
CG Oncology
December 2024

CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.

Biotechnology · Irvine$238.0M Post-IPO Equity
Myome
December 2025

Myome helps identify genes that cause disease and act based on leading science.

Biotechnology · Palo AltoVenture - Series Unknown
Fulcrum Therapeutics
December 2025

Fulcrum Therapeutics is a biotechnology company that focuses on identifying and treating rare genetic diseases at their root cause.

Biotechnology · Cambridge$175.0M Post-IPO Equity
Inscripta
January 2023

Inscripta is a life science technology company that develops digital genome engineering solutions.

Biotechnology · Pleasanton$4.4M Venture - Series Unknown
Replimune Group
November 2024

Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.

Biotechnology · Woburn$140.0M Post-IPO Equity
Velia
January 2022

Velia is a biotech company that discovers and develops the therapeutic potential of human proteins.

Biotechnology · San Diego$55.0M Series A
Invivyd
November 2025

Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.

Biotechnology · Waltham$125.0M Post-IPO Equity
Alector
November 2024

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

Biotechnology · San Francisco$50.0M Post-IPO Debt
Nested Therapeutics
October 2022

Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations.

Biotechnology · Cambridge$90.0M Series A
Arcus Biosciences
October 2025

Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.

Biopharma · Hayward$250.0M Post-IPO Equity
Nurix Therapeutics
October 2025

Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.

Biotechnology · San Francisco$250.0M Post-IPO Equity
Rapt Therapeutics
October 2025

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

Biotechnology · South San Francisco$250.0M Post-IPO Equity
AtaiBeckley
October 2025

AtaiBeckley develops innovative mental health treatments that address significant unmet medical needs.

Biotechnology · Berlin$149.5M Post-IPO Equity
Folx Health
October 2022

Folx Health is a telehealth platform that provides digital healthcare services designed for the LGBTQIA+ community.

Health Care · Boston$30.0M Series B
Solid Biosciences
March 2026

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Biotechnology · Charlestown$240.0M Post Ipo Equity
Seaport Therapeutics
March 2026

Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops neuropsychiatric medicines.

Biopharma · Boston$15.0M Grant
Slate Medicines
February 2026

Slate Medicines develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention.

Biotechnology · Raleigh$130.0M Series A
Third Arc Bio
February 2026

Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.

Biotechnology · Boston$52.0M Series A

Where Foresite Capital invests

Biotechnology22
Health Care19
Therapeutics13
Life Science8
Medical8
Pharmaceutical7

About Foresite Capital's portfolio

How many companies has Foresite Capital invested in?

Foresite Capital has invested in 129 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Foresite Capital invest in?

Foresite Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Life Science, Medical. The firm invests across 18 different industry categories.

What is Foresite Capital's largest investment?

Among tracked funding rounds, Wave Life Sciences received $350.0M in a Post-IPO Equity round. Foresite Capital's total known invested capital is $15.2B.

What is the average investment size for Foresite Capital?

Foresite Capital's average investment size is $143.0M across its portfolio of 129 companies.

What are Foresite Capital's most recent investments?

Recent Foresite Capital portfolio additions include Wave Life Sciences, TenSixteen Bio, Pardes Biosciences, Aeovian Pharmaceuticals, Tasso. These companies were founded in 2020 or later.

Reach the founders behind these 129 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →